1050 J ournal of Medicinal Chemistry, 2002, Vol. 45, No. 5
Goodman et al.
(4) Bondinell, W. E.; Keenan, R. M.; Ali, F. E.; Allen, A. C.; Brosse,
C. W. D.; Eggleston, D. S.; Erhard, K. F.; Haltiwanger, R. C.;
Huffman, W. F.; Hwang, S.-M.; J akas, D. R.; Koster, P. F.; Ku,
T. W.; Lee, C. P.; Nichols, A. J .; Ross, S. T.; Samanen, J . M.;
Valocik, R. E.; Vasko-Moser, J . A.; Venslavsky, J . W.; Wong, A.
S.; Yuan, C.-K. Design of a Potent and Orally Active Nonpeptide
Platelet Fibrinogen Receptor (GPIIb/IIIa) Antagonist. Bioorg.
Med. Chem. Lett. 1994, 2, 897-908.
(5) Egbertson, M. S.; Chang, C. T.-C.; Duggan, M. E.; Gould, R. J .;
Halczenko, W.; Hartman, G. D.; Laswell, W. L.; J r., J . J . L.;
Lynch, R. J .; Manno, P.; Naylor, A. M.; Prugh, J . D.; Ramjit, D.
R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-
Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a
Tyrosine Template as a Mimic for Arg-Gly-Asp. J . Med. Chem.
1994, 37, 2537-2551.
(6) Samanen, J . M.; Ali, F. E.; Barton, L. S.; Bondinell, W. E.;
Burgess, J . L.; Callahan, J . F.; Calvo, R. R.; Chen, W.; Chen, L.;
Erhard, K.; Feuerstein, G.; Heys, R.; Hwang, S.-M.; J akas, D.
R.; Keenan, R. M.; Ku, T. W.; Kwon, C.; Lee, C.-P.; Miller, W.
H.; Newlander, K. A.; Nichols, A.; Parker, M.; Peishoff, C. E.;
Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin,
T. O.; Uzsinskas, I.; Venslavsky, J . W.; Yuan, C.-K.; Huffman,
W. F. Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine
GPIIb/IIIa Integrin Antagonists. J . Med. Chem. 1996, 39, 4867-
4870.
(7) Keenan, R. M.; Miller, W. H.; Kwon, C.; Ali, F. E.; Callahan, J .
F.; Calvo, R. R.; Hwang, S.-M.; Kopple, K. D.; Peishoff, C. E.;
Samanen, J . M.; Wong, A. S.; Yuan, C.-K.; Huffman, W. F.
Discovery of Potent Nonpeptide Vitronectin Receptor Antago-
nists. J . Med. Chem. 1997, 40, 2289-2292.
(19) Aumailley, M.; Gurrath, M.; Miller, G.; Calvete, J .; Timpl, R.;
Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides.
Strong and selective inhibitors of cell adhesion to vitronectin
and laminin fragment P1. FEBS Lett. 1991, 291, 50-54.
(20) Gurrath, M.; Mu¨ller, G.; Kessler, H.; Aumailley, M.; Timpl, R.
Conformation/activity studies of rationally designed potent anti-
adhesive RGD peptides. Eur. J . Biochem. 1992, 210, 911-921.
(21) Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.;
J onczyk, A.; Kessler, H. Structural and Functional Aspects of
RGD-Containing Cyclic Pentapeptides as Highly Potent and
Selective Integrin Rvâ3 Antagonists. J . Am. Chem. Soc. 1996,
118, 7461-7472.
(22) Bach, A. C., II; Espina, J . R.; J ackson, S. A.; Stouten, P. F. W.;
Duke, J . L.; Mousa, S. A.; DeGrado, W. F. Type II′ to Type I
P3-Turn Swap Changes Specificity for Integrins. J . Am. Chem.
Soc. 1996, 118, 293-294.
(23) Burgess, K.; Lim, D. Synthesis and Solution Conformation of
Cyclo[RGDRGD]: A Cyclic Peptide with Selectivity for the Rvâ3
Receptor. J . Med. Chem. 1996, 39, 4520-4526.
(24) Tran, T.-A.; Mattern, R.-H.; Zhu, Q.; Goodman, M. A Novel RGD
Containing Dodecapeptidomimetic which exhibits Selective Bind-
ing to the Rvâ3 Receptor. Bioorg. Med. Chem. Lett. 1997, 7, 997-
1002.
(25) Dechantsreiter, M. A.; Planker, E.; Matha¨, B.; Lohof, E.; Ho¨lze-
mann, G.; J onczyk, A.; Kessler, H. N-Methylated Cyclic RGD
Peptides as Highly Active and Selective Rvâ3 Integrin Antago-
nists. J . Med Chem. 1999, 42, 3033-3040.
(26) Kraft, S.; Diefenbach, B.; Mehta, R.; J onczyk, A.; Luckenbach,
G. A.; Goodman, S. L. Definition of an Unexpected Ligand
Recognition Motif for Rvâ6 Integrin. J . Biol. Chem. 1999, 274,
1979-1985.
(8) Nicolaou, K. C.; Trujillo, J . I.; J andeleit, B.; Chibale, K.;
Rosenfeld, M.; Diefenbach, B.; Cheresh, D. A.; Goodman, S. L.
Design, Synthesis and Biological Evaluation of Nonpeptide
Integrin Antagonists. Bioorg. Med. Chem. 1998, 6, 1185-1208.
(9) Gibson, C.; Goodman, S. L.; Hahn, D.; Ho¨lzemann, G.; Kessler,
H. Novel Solid-Phase Synthesis of Azapeptides and Azapeptoides
via Fmoc-Strategy and Its Application in the Synthesis of RGD-
Mimetics. J . Org. Chem. 1999, 64, 7388-7394.
(10) Lark, M. W.; Stroup, G. B.; Hwang, S. M.; J ames, I. E.; Rieman,
D. J .; Drake, F. H.; Bradbeer, J . N.; Mathur, A.; Erhard, K. F.;
Newlander, K. A.; Ross, S. T.; Salyers, K. L.; Smith, B. R.; Miller,
W. H.; Huffman, W. F.; Gowen, M. Design and Characterization
of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Recep-
tor Antagonist SB 265123 for Prevention of Bone Loss in
Osteoporosis. J . Pharmacol. Exp. Ther. 1999, 291, 612-617.
(11) Mousa, S. A.; Lorelli, W.; Mohamed, S.; Batt, D. G.; J adhav, P.
K.; Reilly, T. M. Rvâ3 Integrin Binding Affinity and Specificity
of SM256 in Various Species. J . Cardiovasc. Pharmacol. 1999,
33, 641-646.
(12) Gibson, C.; Sulyok, G. A. G.; Hahn, D.; Goodman, S. L.;
Ho¨lzemann, G.; Kessler, H. Nonpeptidic Rvâ3 Integrin Antago-
nist Libraries: On-Bead Screening and Mass Spectrometric
Identification without Tagging. Angew. Chem. Int. Ed. Engl.
2001, 40, 165-169.
(13) Sulyok, G. A. G.; Gibson, C.; Goodman, S. L.; Ho¨lzemann, G.;
Wiesner, M.; Kessler, H. Solid-Phase Synthesis of a Nonpeptide
RGD Mimetic Library: New Selective Rvâ3 Integrin Antago-
nists. J . Med. Chem. 2001, 44, 1938-1950.
(27) Koivunen, E.; Wang, B.; Ruoslahti, E. Isolation of a highly
specific ligand for the R5â1 integrin from a phage display library.
J . Cell Biol. 1994, 124, 373-380.
(28) Huang, X. Z.; Wu, J . F.; Cass, D.; Erle, D. J .; Corry, D.; Young,
S. G.; Farese, R. V., J r.; Sheppard, D. Inactivation of the integrin
â6 subunit gene reveals a role of epithelial integrins in regulat-
ing inflammation in the lung and skin. J . Cell Biol. 1996, 133,
921-928.
(29) Agrez, M.; Chen, A.; Cone, R. I.; Pytela, R.; Sheppard, D. The
Rvâ6 integrin promotes proliferation of colon carcinoma cells
through a unique region of the â6 cytoplasmic domain. J . Cell
Biol. 1994, 127, 547-556.
(30) Breuss, J . M.; Gallo, J .; DeLisser, H. M.; Klimanskaya, I. V.;
Folkesson, H. G.; Pittet, J . F.; Nishimura, S. L.; Aldape, K.;
Landers, D. V.; Carpenter, W.; et al. Expression of the â6
integrin subunit in development, neoplasia and tissue repair
suggests a role in epithelial remodeling. J . Cell Sci. 1995, 108,
2241-2251.
(31) J ones, J .; Watt, F. M.; Speight, P. M. J . Oral. Pathol. Med. 1997,
26, 63-68.
(32) Clark, R. A.; Ashcroft, G. S.; Spencer, M. J .; Larjava, H.;
Ferguson, M. W. Reepithelialization of normal human excisional
wounds is associated with a switch from Rvâ5 to Rvâ6 integrins.
Br. J . Dermatol. 1996, 135, 46-51.
(33) Haapasalmi, K.; Zhang, K.; Tonnesen, M.; Olerud, J .; Sheppard,
D.; Salo, T.; Kramer, R.; Clark, R. A.; Uitto, V. J .; Larjava, H.
Keratinocytes in human wounds express Rvâ6 integrin. J . Invest.
Dermatol. 1996, 106, 42-48.
(34) Huang, X.; Wu, J .; Spong, S.; Sheppard, D. The integrin Rvâ6 is
critical for keratinocyte migration on both its known ligand,
fibronectin, and on vitronectin. J . Cell Sci. 1998, 111, 2189-
2195.
(35) Niu, J .; Gu, X.; Turton, J .; Meldrum, C.; Howard, E. W.; Agrez,
M. Integrin-mediated signaling of gelatinase B secretion in colon
cancer cells. Biochem. Biophys. Res. Commun. 1998, 249, 287-
291.
(36) Agrez, M.; Gu, X.; Turton, J .; Meldrum, C.; Niu, J .; Antalis, T.;
Howard, E. W. The Rvâ6 integrin induces gelatinase B secretion
in colon cancer cells. Int. J . Cancer 1999, 81, 90-97.
(37) Munger, J . S.; Huang, X.; Kawakatsu, H.; Griffiths, M. J . D.;
Dalton, S. L.; Wu, J .; Pittet, J .-F.; Kaminski, N.; Garat, C.;
Matthay, M. A.; Rifkin, D. B.; Sheppard, D. The Integrin Rvâ6
Binds and Activates Latent TGF-â1: A Mechanism for Regulat-
ing Pulmonary Inflammation and Fibrosis. Cell 1999, 96, 319-
328.
(38) Naik, U. P.; Parise, L. V. Structure and function of platelet
aIIb33. Curr. Opin. Hematol. 1997, 4, 317-322.
(39) Varner, J . A.; Cheresh, D. A. Tumor angiogenesis and the role
of vascular cell integrin Rvâ3. Important Adv. Oncol. 1996, 69-
87.
(40) Choi, E. T.; Engel, L.; Callow, A. D.; Sun, S.; Trachtenberg, J .;
Santoro, S.; Ryan, U. S. Inhibition of neointimal hyperplasia by
blocking Rvâ3 integrin with a small peptide antagonist Gpen-
GRGDSPCA. J . Vasc. Surg. 1994, 19, 125-134.
(14) Ho¨lzemann, G. Recent advances in Rvâ3 integrin inhibitors.
IDrugs 2001, 4, 72-81.
(15) Lin, K. C.; Ateeq, H. S.; Hsiung, S. H.; Chong, L. T.; Zimmerman,
C. N.; Castro, A.; Lee, W. C.; Hammond, C. E.; Kalkunte, S.;
Chen, L. L.; Pepinsky, R. B.; Leone, D. R.; Sprague, A. G.;
Abraham, W. M.; Gill, A.; Lobb, R. R.; Adams, S. P. Selective,
tight-binding inhibitors of integrin ta4pl that inhibit allergic
airway responses. J . Med. Chem. 1999, 42, 920-934.
(16) Cue, D.; Southern, S. O.; Southern, P. J .; Prabhakar, J .; Lorelli,
W.; Smallheer, J . M.; Mousa, S. A.; Cleary, P. P. A nonpeptide
integrin antagonist can inhibit epithelial cell ingestion of Strep-
tococcus pyogenes by blocking formation of integrin R5â1-
fibronectin-M1 protein complexes. Proc. Natl. Acad. Sci. U.S.A.
2000, 97, 2858-2863.
(17) Kloczewiak, M.; Timmons, S.; Lukas, T. J .; Hawiger, J . Platelet
receptor recognition site on human fibrinogen. Synthesis and
structure-function relationship of peptides corresponding to the
carboxy-terminal segment of the γ-chain. Biochemistry 1984, 23,
1767-17.
(18) Peishoff, C. E.; Ali, F. E.; Bean, J . W.; Calvo, R.; D’Ambrosio, C.
A.; Eggleston, D. S.; Hwang, S. M.; Kline, T. P.; Koster, P. F.;
Nichols, A.; Powers, D.; Romoff, T.; Samanen, J . M.; Stadel, J .;
Vasko, J . A.; Kopple, K. D. Investigation of Conformational
Specificity at GPIIb/IIIa: Evaluation of Conformationally Con-
strained RGD Peptides. J . Med. Chem. 1992, 35, 3962-3969.